logo Epi Result

Good research. Valid results. Better decisions.


A narrative review of the safety and efficacy of aspirin in prostate and other cancers

There is growing epidemiological evidence that daily aspirin has a role in the prevention and remission of some cancers, including prostate cancer. Therefore, a review of journal reports published between 1990 and 2013 was performed in order to summarize evidence on the safety and efficacy of aspirin in the prevention and / or adjuvant treatment of prostate and other cancers.

The articles in the final data set included meta-analyses of cancer outcomes from studies originally designed to investigate the effect of daily aspirin on cardiovascular outcomes. These studies demonstrated variable effect sizes, which consistently showed a protective effect of aspirin  for most types and stages of neoplastic disease. Basic research studies elucidated the possible mechanism by which aspirin is thought to prevent incident cancer and also attenuate the progression of established cancer. The narrative review critiqued the current methodologies used to investigate this topic.

Although there is growing evidence from observational epidemiologic studies that daily aspirin has a role in the prevention and adjuvant therapy of some cancers, it is concluded that there is currently too limited experimental evidence on using aspirin as a prophylactic or adjuvant treatment for cancer to withstand rigorous regulatory assessment, and hence enable preventative and /or adjuvant public health recommendations in high risk populations in South Africa and elsewhere.

Access the original, full article as submitted by the authors.

By Tohlang Sehloho, National Department of Health, Republic of South Africa (SehloT@health.gov.za) and Neo Ledibane, Division of Biostatistics and Epidemiology, School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Republic of South Africa. 

Print this article

Continue reading...

Africa Health News

Africa Health News is a new website that brings together health news, events and career opportunities from African countries. Monthly updates are send out to a large group of interested subscribers. I started this website in the beginning of 2016 and Emily Christopher, Megan Harker and Steven Nonde are currently writing articles for it.

This article is published in the category:
Epidemiology in the news
One Response leave one →
    GIRAVOYA BONFACE

    Aspirin has also been demonstrated to prevent pre-eclampsia when a daily dose of 150 mg is administered to expectant women from 12 weeks of pregnancy.

    Reply

Leave a Reply